A trial to assess the effect of adalimumab, versus salazopyrine or methotrexate, on articular and gastrointestinal inflammation in patients with enteropathic spondyloarthritis

Trial Profile

A trial to assess the effect of adalimumab, versus salazopyrine or methotrexate, on articular and gastrointestinal inflammation in patients with enteropathic spondyloarthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2015

At a glance

  • Drugs Adalimumab (Primary) ; Methotrexate; Sulfasalazine
  • Indications Crohn's disease; Spondylarthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Aug 2015 New trial record
    • 10 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top